terutroban

a thromboxan receptor antagonist

Also Known As:

3-((6-amino-(4-chlorobenzenesulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl)propionic acid; 3-((6R)-6-(((4-chlorophenyl)sulfonyl)amino)-2-methyl-5,6,7,8 tetrahydro-1-naphthalenyl) propanoic acid, sodium salt; S 18204; S-18204; S-18885; S-18886; S18886; terutroban, sodium salt

Networked: 45 relevant articles (8 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hennerici, Michael G: 7 articles (03/2019 - 01/2009)
2.	Ford, Ian: 6 articles (03/2019 - 04/2010)
3.	Amarenco, Pierre: 5 articles (03/2019 - 11/2011)
4.	Chamorro, Angel: 5 articles (03/2019 - 01/2009)
5.	Rothwell, Peter M: 5 articles (03/2019 - 11/2011)
6.	PERFORM Study Investigators: 5 articles (10/2013 - 01/2009)
7.	Bousser, Marie-Germaine: 4 articles (03/2019 - 11/2011)
8.	Fisher, Marc: 4 articles (03/2019 - 11/2011)
9.	Fox, Kim M: 4 articles (03/2019 - 11/2011)
10.	Mattle, Heinrich P: 4 articles (03/2019 - 11/2011)

Related Diseases

1.	Ischemic Stroke 04/01/2010 - "The PERFORM Vascular Project will investigate terutroban's effect on vascular structure and function in patients with a history of ischemic stroke or TIAs." 01/01/2009 - "The PERFORM Study will explore the benefits of terutroban in secondary prevention of ischemic stroke. " 04/01/2010 - "Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial." 01/01/2009 - "Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study." 01/01/2009 - "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population."
2.	Transient Ischemic Attack 04/01/2010 - "Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial." 01/01/2009 - "Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study." 01/01/2009 - "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population." 10/09/2013 - "Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population." 01/01/2009 - "The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study is an international, multicenter, randomized, double-blind, parallel-group study in patients aged > or =55 years who have suffered ischemic strokes (<3 months) or transient ischemic attacks (<8 days), and who are stable at inclusion with no intracranial hemorrhage or nonischemic neurological diseases. "
3.	Stroke (Strokes) 06/11/2011 - "Vascular events after stroke: terutroban fails to PERFORM." 05/07/2010 - "Terutroban is presently being tested in PAD and stroke prevention. " 01/01/2009 - "The potential therapeutic applications of terutroban in the prevention of atherothrombosis, particularly in the cerebrovascular and cardiovascular fields including stroke and coronary artery disease, are based on a number of convincing experimental animal and clinical studies. " 01/01/2012 - "Despite great expectations on this drug supported by a large body of preclinical and clinical evidence and pathophysiological rationale, the PERFORM trial failed to demonstrate the superiority of terutroban over aspirin in secondary prevention of cerebrovascular and cardiovascular events among ~20,000 patients with stroke. " 07/01/2010 - "This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor antagonist, on stroke incidence in spontaneously hypertensive stroke-prone rats (SHRSP). "
4.	Atherosclerosis 03/01/2011 - "These findings provide mechanistic data supporting the beneficial effects of terutroban in preventing or retarding atherogenesis." 04/01/2010 - "The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients. " 11/01/2006 - "Several reports using experimental animal models of atherosclerosis indicated that S18886 caused a regression of advanced atherosclerosis. " 08/01/2005 - "S18886 was compared with control in an experimental model of established aortic atherosclerosis in New Zealand White rabbits (n=10). " 06/01/2011 - "Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis."
5.	Thrombosis (Thrombus) 11/01/2006 - "For the primary thrombosis study in left circumflex (LCX) coronary artery, 26 dogs were randomized to receive either vehicle (n = 7) or intravenous S18886 (0.3 mg/kg, n = 6; 1.0 mg/kg, n = 6; and 3.0 mg/kg, n = 7). " 07/01/2010 - "These data support clinical development of terutroban in the prevention of cerebrovascular and cardiovascular complications of atherothrombosis." 11/01/2006 - "Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis." 05/01/2005 - "S18886 completely inhibited thrombosis in all dogs in approximately 5-10 minutes. " 05/01/2005 - "After thrombosis had been obtained in 11 dogs, S18886 (300 microg/kg bolus) was administered IV. Heart rate, systemic blood pressure, and coronary blood flow were continuously recorded. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Thromboxane Receptors (Thromboxane Receptor)
3.	Thromboxanes
4.	Clopidogrel (Plavix)
5.	prostaglandin endoperoxide receptor
6.	Creatinine
7.	Insulin (Novolin)
8.	Glucose (Dextrose)
9.	terutroban
10.	Prostaglandins

Related Therapies and Procedures

1.	Secondary Prevention
2.	Ligation
3.	Therapeutics
4.	Stents
5.	Oral Administration